N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT07792954

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur. During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.

Interventions

  • Berobenatide (Drug)
    Solution for injection
  • Placebo (Other)
    Solution for injection

Eligibility criteria

Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant recent weight change (\>5% within 3 months). * Type 1 diabetes mellitus. * History of pancreatitis. * Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2). * Recent bariatric surgery or obesity procedures. * Pregnancy or breastfeeding.

Conditions

Obesity Overweight

Locations

  • The Second People's Hospital of Hefei — Hefei, Anhui, China
  • Peking University People's Hospital — Beijing, Beijing Municipality, China
  • Beijing Friendship Hospital — Beijing, Beijing Municipality, China
  • Beijing Pinggu Hospital — Beijing, Beijing Municipality, China
  • Beijing Tsinghua Changgung Hospital — Beijing, Beijing Municipality, China
  • Chongqing People's Hospital — Chongqing, Chongqing Municipality, China
  • Chongqing University Three Gorges Hospital — Chongqing, Chongqing Municipality, China
  • Huizhou Central People's Hospital — Huizhou, Guangdong, China
  • Harrison International Peace Hospital — Hengshui, Hebei, China
  • The Second Hospital of Hebei Medical University — Shijiazhuang, Hebei, China
  • The Fourth Hospital of Harbin Medical University — Harbin, Heilongjiang, China
  • Luoyang First People's Hospital — Luoyang, Henan, China
  • The First Affiliated Hospital of Henan University of Science &Technology — Luoyang, Henan, China
  • The Second Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China
  • Shiyan Taihe Hospital — Shiyan, Hubei, China
  • Wuhan Third Hospital — Wuhan, Hubei, China
  • Changzhou Second People's Hospital — Changzhou, Jiangsu, China
  • The Second Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China
  • Nanjing First Hospital — Nanjing, Jiangsu, China
  • Affiliated Hospital of Nantong University — Nantong, Jiangsu, China
  • Affiliated Hospital of Jiangsu University — Zhenjiang, Jiangsu, China
  • Jiangxi Provincial People's Hospital — Nanchang, Jiangxi, China
  • Pingxiang People's Hospital — Pingxiang, Jiangxi, China
  • The Second Hospital of Jilin University — Changchun, Jilin, China
  • The First Affiliated Hospital of Xi'an Medical University — Xi'an, Shaanxi, China
  • Jinan Central Hospital — Jinan, Shandong, China
  • Zhongshan Hospital,Fudan University — Shanghai, Shanghai Municipality, China
  • Shanghai Tenth People's Hospital — Shanghai, Shanghai Municipality, China
  • The Fifth People's Hospital of Shanghai — Shanghai, Shanghai Municipality, China
  • Pudong New Area People's Hospital Shanghai — Shanghai, Shanghai Municipality, China
  • Hangzhou First People's Hospital — Hangzhou, Zhejiang, China
  • Huzhou Central Hospital — Huzhou, Zhejiang, China
  • The first affiliated hospital of Ningbo university — Ningbo, Zhejiang, China
  • Tianjin Medical University General Hospital — Tianjin, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record